Anika Therapeutics (ANIK) 10-Q 2 Nov 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Oct. 26, 2023
Document Information [Line Items]
Entity Central Index Key	0000898437
Entity Registrant Name	Anika Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-14027
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3145961
Entity Address, Address Line One	32 Wiggins Avenue
Entity Address, City or Town	Bedford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01730
City Area Code	781
Local Phone Number	457-9000
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ANIK
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		14,640,886

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 70,651	$ 86,327
Accounts receivable, net	34,682	34,627
Inventories, net	43,724	39,765
Prepaid expenses and other current assets	7,721	8,828
Total current assets	156,778	169,547
Property and equipment, net	45,937	48,279
Right-of-use assets	29,053	30,696
Other long-term assets	18,951	17,219
Deferred tax assets	1,424	1,449
Intangible assets, net	68,762	74,599
Goodwill	7,253	7,339
Total assets	328,158	349,128
Current liabilities:
Accounts payable	8,251	9,074
Accrued expenses and other current liabilities	19,813	18,840
Total current liabilities	28,064	27,914
Other long-term liabilities	400	398
Deferred tax liability	1,955	6,436
Lease liabilities	27,253	28,817
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively		0
Common stock, $0.01 par value; 90,000 shares authorized, 14,825 issued and 14,637 outstanding and 14,625 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	146	146
Additional paid-in-capital	85,852	81,141
Accumulated other comprehensive loss	(6,564)	(6,443)
Retained earnings	191,052	210,719
Total stockholders’ equity	270,486	285,563
Total liabilities and stockholders’ equity	$ 328,158	$ 349,128

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Sep. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,250	1,250
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	90,000	90,000
Common stock, shares issued (in shares)	14,825	14,625
Common stock, shares outstanding (in shares)	14,637	14,625

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 41,465	$ 40,264	$ 123,691	$ 116,614
Cost of revenue	16,521	17,485	46,932	47,169
Gross Profit	24,944	22,779	76,759	69,445
Operating expenses:
Research and development	7,791	7,301	25,105	20,433
Selling, general and administrative	24,827	21,276	75,512	61,745
Total operating expenses	32,618	28,577	100,617	82,178
Loss from operations	(7,674)	(5,798)	(23,858)	(12,733)
Interest and other income, net	635	436	1,735	378
Loss before income taxes	(7,039)	(5,362)	(22,123)	(12,355)
Benefit from income taxes	(463)	(1,187)	(2,456)	(2,404)
Net income (loss)	$ (6,576)	$ (4,175)	$ (19,667)	$ (9,951)
Net loss per share:
Basic (in dollars per share)	$ (0.45)	$ (0.29)	$ (1.34)	$ (0.68)
Diluted (in dollars per share)	$ (0.45)	$ (0.29)	$ (1.34)	$ (0.68)
Weighted average common shares outstanding:
Basic (in shares)	14,635	14,603	14,659	14,542
Diluted (in shares)	14,635	14,603	14,659	14,542
Net income (loss)	$ (6,576)	$ (4,175)	$ (19,667)	$ (9,951)
Foreign currency translation adjustment	(407)	(851)	(121)	(1,779)
Comprehensive loss	$ (6,983)	$ (5,026)	$ (19,788)	$ (11,730)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Restricted Stock Units (RSUs) [Member] Common Stock Outstanding [Member]	Restricted Stock Units (RSUs) [Member] Additional Paid-in Capital [Member]	Restricted Stock Units (RSUs) [Member] Retained Earnings [Member]	Restricted Stock Units (RSUs) [Member] AOCI Attributable to Parent [Member]	Restricted Stock Units (RSUs) [Member]	Common Stock Outstanding [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2021						14,441,000
Balance at Dec. 31, 2021						$ 144	$ 67,081	$ 225,578	$ (5,718)	$ 287,085
Issuance of common stock for equity awards (in shares)						1,000
Issuance of common stock for equity awards						$ 0	15	0	0	15
Vesting of restricted stock units (in shares)	106,000
Vesting of restricted stock units	$ 1	$ (1)	$ 0	$ 0	$ 0
Stock-based compensation expense						$ 0	2,545	0	0	2,545
Retirement of common stock for minimum tax withholdings (in shares)						(30,000)
Retirement of common stock for minimum tax withholdings						$ 0	(844)	0	0	(844)
Net income (loss)						0	0	(2,933)	0	(2,933)
Other comprehensive income (loss)						0	0	0	(81)	(81)
Stock-based compensation expense						$ 0	2,545	0	0	2,545
Balance (in shares) at Mar. 31, 2022						14,518,000
Balance at Mar. 31, 2022						$ 145	68,796	222,645	(5,799)	285,787
Balance (in shares) at Dec. 31, 2021						14,441,000
Balance at Dec. 31, 2021						$ 144	67,081	225,578	(5,718)	287,085
Net income (loss)										(9,951)
Balance (in shares) at Sep. 30, 2022						14,607
Balance at Sep. 30, 2022						$ 146	76,661	215,627	(7,497)	284,937
Balance (in shares) at Mar. 31, 2022						14,518,000
Balance at Mar. 31, 2022						$ 145	68,796	222,645	(5,799)	285,787
Vesting of restricted stock units (in shares)	61,000
Vesting of restricted stock units	$ 1	(1)	0	0	0
Stock-based compensation expense						$ 0	4,081	0	0	4,081
Retirement of common stock for minimum tax withholdings (in shares)						(1,000)
Retirement of common stock for minimum tax withholdings						$ 0	(25)	0	0	(25)
Net income (loss)						0	0	(2,843)	0	(2,843)
Other comprehensive income (loss)						$ 0	0	0	(847)	(847)
Issuance of ESPP shares (in shares)						20,000
Issuance of ESPP shares						$ 0	0	0	0	0
Stock-based compensation expense						$ 0	4,081	0	0	4,081
Balance (in shares) at Jun. 30, 2022						14,598,000
Balance at Jun. 30, 2022						$ 146	72,851	219,802	(6,646)	286,153
Vesting of restricted stock units (in shares)						11,000
Vesting of restricted stock units						$ 0	0	0	0	0
Stock-based compensation expense						$ 0	3,876	0	0	3,876
Retirement of common stock for minimum tax withholdings (in shares)						(2,000)
Retirement of common stock for minimum tax withholdings						$ 0	(66)	0	0	(66)
Net income (loss)						0	0	(4,175)	0	(4,175)
Other comprehensive income (loss)						0	0	0	(851)	(851)
Stock-based compensation expense						$ 0	3,876	0	0	3,876
Balance (in shares) at Sep. 30, 2022						14,607
Balance at Sep. 30, 2022						$ 146	76,661	215,627	(7,497)	284,937
Balance (in shares) at Dec. 31, 2022						14,625,000
Balance at Dec. 31, 2022						$ 146	81,141	210,719	(6,443)	285,563
Issuance of common stock for equity awards (in shares)						1,000
Issuance of common stock for equity awards						$ 0	7	0	0	7
Vesting of restricted stock units (in shares)	177,000
Vesting of restricted stock units	$ 2	(2)	0	0	0
Stock-based compensation expense						$ 0	3,717	0	0	3,717
Retirement of common stock for minimum tax withholdings (in shares)						(62,000)
Retirement of common stock for minimum tax withholdings						$ (1)	(1,620)	0	0	(1,621)
Net income (loss)						0	0	(10,350)	0	(10,350)
Other comprehensive income (loss)						0	0	0	272	272
Stock-based compensation expense						$ 0	3,717	0	0	3,717
Balance (in shares) at Mar. 31, 2023						14,741,000
Balance at Mar. 31, 2023						$ 147	83,243	200,369	(6,171)	277,588
Balance (in shares) at Dec. 31, 2022						14,625,000
Balance at Dec. 31, 2022						$ 146	81,141	210,719	(6,443)	285,563
Net income (loss)										(19,667)
Balance (in shares) at Sep. 30, 2023						14,637,000
Balance at Sep. 30, 2023						$ 146	85,852	191,052	(6,564)	270,486
Balance (in shares) at Mar. 31, 2023						14,741,000
Balance at Mar. 31, 2023						$ 147	83,243	200,369	(6,171)	277,588
Issuance of common stock for equity awards (in shares)						1,000
Issuance of common stock for equity awards						$ 0	30	0	0	30
Vesting of restricted stock units (in shares)	70,000
Vesting of restricted stock units	$ 1	$ (1)	$ 0	$ 0	$ 0
Stock-based compensation expense						$ 0	4,150	0	0	4,150
Retirement of common stock for minimum tax withholdings (in shares)						(16,000)
Retirement of common stock for minimum tax withholdings						$ 0	(432)	0	0	(432)
Net income (loss)						0	0	(2,741)	0	(2,741)
Other comprehensive income (loss)						$ 0	0	0	14	14
Issuance of ESPP shares (in shares)						20,000
Issuance of ESPP shares						$ 0	456	0	0	456
Stock-based compensation expense						$ 0	4,150	0	0	4,150
Repurchase of common stock (in shares)						(159,000)
Repurchase of common stock						$ (1)	(5,049)	0	0	(5,050)
Balance (in shares) at Jun. 30, 2023						14,657,000
Balance at Jun. 30, 2023						$ 147	82,397	197,628	(6,157)	274,015
Vesting of restricted stock units (in shares)						12,000
Vesting of restricted stock units						$ 0	0	0	0	0
Stock-based compensation expense						$ 0	3,561	0	0	3,561
Retirement of common stock for minimum tax withholdings (in shares)						(3,000)
Retirement of common stock for minimum tax withholdings						$ 0	(107)	0	0	(107)
Net income (loss)						0	0	(6,576)	0	(6,576)
Other comprehensive income (loss)						0	0	0	(407)	(407)
Stock-based compensation expense						$ 0	3,561	0	0	3,561
Repurchase of common stock (in shares)						(29,000)
Repurchase of common stock						$ (1)	1	0	0	0
Balance (in shares) at Sep. 30, 2023						14,637,000
Balance at Sep. 30, 2023						$ 146	$ 85,852	$ 191,052	$ (6,564)	$ 270,486

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net income (loss)	$ (19,667)	$ (9,951)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	4,806	4,984
Amortization of acquisition related intangible assets	5,837	5,837
Non-cash operating lease cost	1,633	1,322
Loss on disposal of property and equipment	1,852	0
Stock-based compensation expense	11,428	10,502
Deferred income taxes	(4,484)	(3,491)
Provision for credit losses	74	379
Provision for inventory	2,607	3,701
Changes in operating assets and liabilities:
Accounts receivable, net	(201)	(4,983)
Inventories	(8,257)	(3,933)
Prepaid expenses, other current and long-term assets	818	(456)
Accounts payable	(1,319)	533
Operating lease liabilities	(1,575)	(1,054)
Accrued expenses, other current and long-term liabilities	914	115
Income taxes	108	423
Net cash (used in) provided by operating activities	(5,426)	3,928
Cash flows from investing activities:
Purchases of property and equipment	(3,587)	(4,957)
Net cash used in investing activities	(3,587)	(4,957)
Cash flows from financing activities:
Proceeds from employee stock purchase program	456	0
Cash paid for tax withheld on vested restricted stock awards	(2,159)	(935)
Proceeds from exercises of equity awards	37	15
Payments made on finance leases	0	(284)
Contingent consideration payout	0	(4,315)
Repurchases of common stock	(5,000)	0
Net cash used in financing activities	(6,666)	(5,519)
Exchange rate impact on cash	3	(61)
Decrease in cash and cash equivalents	(15,676)	(6,609)
Cash and cash equivalents at beginning of period	86,327	94,386
Cash and cash equivalents at end of period	70,651	87,777
Non-cash investing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	0	11,589
Purchases of property and equipment included in accounts payable and accrued expenses	$ 749	$ 108

Note 1 - Nature of Business

Note 1 - Nature of Business	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of Business Anika Therapeutics, Inc. (the “Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, sports medicine and Arthrosurface joint solutions. In early 2020, 30 The Company is subject to risks common to companies in the life sciences industry including, but not

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been or omitted pursuant to SEC rules and regulations relating to interim financial statements. The December 31, 2022 The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10 December 31, 2022. three nine September 30, 2023 not December 31, 2023. Segment Information Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker as of September 30, 2023 280, Segment Reportin one

Note 3 - Accounts Receivable

Note 3 - Accounts Receivable	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	3. Accounts Receivable, net The Company estimates an allowance for credit losses with its accounts receivable resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer creditworthiness, current and reasonable and supportable forecasts of future economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms. The components of the Company’s accounts receivable are as follows: As of As of September 30, December 31, 2023 2022 Accounts Receivable $ 36,256 $ 36,235 Less: Allowance for credit losses 1,574 1,608 Net balance, end of period $ 34,682 $ 34,627 A summary of activity in the allowance for credit losses is as follows: As of September 30, 2023 2022 Balance, beginning of the period $ 1,608 $ 1,442 Amounts provided 353 448 Amounts recovered (279 ) (60 ) Amounts written off (101 ) (124 ) Translation adjustments (7 ) (140 ) Balance, end of period $ 1,574 $ 1,566

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. Fair Value Measurements The Company has certain cash equivalents in money market funds that are classified within Level 1 not no nine September 30, 2023 2022. The classification of the Company’s cash equivalents within the fair value hierarchy was as follows: September 30, Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Amortized 2023 (Level 1) (Level 2) (Level 3) Cost Cash equivalents: Money Market Funds $ 51,817 $ 51,817 $ - $ - $ 51,817 December 31, Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Amortized 2022 (Level 1) (Level 2) (Level 3) Cost Cash equivalents: Money Market Funds $ 67,801 $ 67,801 $ - $ - $ 67,801

Note 5 - Inventories

Note 5 - Inventories	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventories Inventories consist of the following: September 30, December 31, 2023 2022 Raw materials $ 16,044 $ 20,535 Work-in-process 17,508 10,648 Finished goods 28,556 25,306 Total $ 62,108 $ 56,489 Inventories $ 43,724 $ 39,765 Other long-term assets 18,384 16,724 Total $ 62,108 $ 56,489 Inventories are stated net of inventory reserves of approximately $11.5 million and $9.9 million, as of September 30, 2023 December 31, 2022,

Note 6 - Intangible Assets

Note 6 - Intangible Assets	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. Intangible Assets, net Intangible assets, net as of September 30, 2023 December 31, 2022 December 31, Nine Months Ended September 30, 2023 2022 Less: Accumulated Weighted Currency Less: Average Gross Translation Accumulated Net Book Net Book Useful Value Adjustment Amortization Value Value Life Developed technology $ 89,580 $ (1,608 ) $ (28,032 ) $ 59,940 $ 64,286 15 IPR&D 2,656 (1,006 ) - 1,650 1,650 Indefinite Customer relationships 9,000 - (3,302 ) 5,698 6,373 10 Distributor relationships 4,700 (415 ) (4,285 ) - - 5 Patents 1,000 (189 ) (716 ) 95 131 16 Tradenames 5,200 - (3,821 ) 1,379 2,159 5 Total $ 112,136 $ (3,218 ) $ (40,156 ) $ 68,762 $ 74,599 13 The aggregate amortization expense related to intangible assets was $1.9 million for each of the three September 30, 2023 2022, nine September 30, 2023 2022,

Note 7 - Goodwill

Note 7 - Goodwill	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Goodwill Disclosure [Text Block]	7. Goodwill The Company assesses goodwill for impairment annually, or, under certain circumstances, more frequently, such as when events or changes in circumstances indicate there may Changes in the carrying value of goodwill for the nine September 30, 2023 Nine Months Ended September 30, 2023 Balance, beginning of period $ 7,339 Effect of foreign currency adjustments (86 ) Balance, ending of period $ 7,253

Note 8 - Accrued Expenses

Note 8 - Accrued Expenses	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	8. Accrued Expenses Accrued expenses consist of the following: September 30, December 31, 2023 2022 Compensation and related expenses $ 10,966 $ 11,303 Professional fees 3,227 3,145 Operating lease liability - current 2,054 2,073 Discontinuation of software implementation project 1,904 - Income taxes payable 819 810 Clinical trial costs 330 999 Other 513 510 Total $ 19,813 $ 18,840

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may not third September 30, 2023 December 31, 2022 no The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not On October 21, 2021, April 24, 2023, March 31, 2023 April 2023

Note 10 - Revenue and Geographi

Note 10 - Revenue and Geographic Information	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	10. Revenue and Geographic Information Revenue by product family is as follows: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 OA Pain Management $ 24,888 $ 24,476 $ 76,855 $ 69,533 Joint Preservation and Restoration 13,470 11,821 39,583 36,055 Non-Orthopedic 3,107 3,967 7,253 11,026 $ 41,465 $ 40,264 $ 123,691 $ 116,614 Effective January 1, 2023, three September 30, 2023 2022, nine September 30, 2023 2022, Revenue from the Company’s sole significant customer, DePuy Synthes Mitek Sports Medicine, part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 44% and 45% for the three September 30, 2023 2022, nine September 30, 2023 2022, Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue were as follows: Three Months Ended September 30, 2023 2022 Percentage of Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 30,831 74 % $ 31,093 77 % Europe 5,420 13 % 4,885 12 % Other 5,214 13 % 4,286 11 % Total $ 41,465 100 % $ 40,264 100 % Nine Months Ended September 30, 2023 2022 Percentage of Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 90,986 74 % $ 87,552 75 % Europe 16,757 13 % 15,973 14 % Other 15,948 13 % 13,089 11 % Total $ 123,691 100 % $ 116,614 100 %

Note 11 - Equity Incentive Plan

Note 11 - Equity Incentive Plan	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	11. Equity Incentive Plan Equity Incentive Plan The Anika Therapeutics, Inc. 2017 “2017 June 13, 2017 June 18, 2019, June 16, 2020, June 16, 2021, June 8, 2022 June 14, 2023. June 14, 2023, 2017 2017 may 2017 two no may 2017 September 30, 2023 2017 The Anika Therapeutics, Inc. 2021 November 4, 2021. may not 2017 September 30, 2023 The Company may three ten The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of revenue $ 181 $ 242 $ 532 $ 645 Research & development 304 397 1,474 1,267 Selling, general & administrative 3,076 3,237 9,422 8,590 Total stock-based compensation expense $ 3,561 $ 3,876 $ 11,428 $ 10,502 Stock Options Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at 110% of the market price of the Company’s common stock on the date of grant. Options generally vest in equal annual installments over a period of three 10 The following summarizes the activity under the Company’s stock option plans: Weighted Average Weighted Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Options Price (in years) (in thousands) Outstanding as of December 31, 2022 1,530,703 $ 34.93 Granted 402,403 $ 28.63 Exercised (2,034 ) $ 18.30 $ 20 Forfeited and canceled (100,628 ) $ 36.40 Outstanding as of September 30, 2023 1,830,444 $ 33.84 7.8 $ 10 Vested, September 30, 2023 975,230 $ 36.70 6.9 $ 0 Vested or expected to vest, September 30, 2023 1,830,444 $ 33.84 7.8 $ 10 The aggregate intrinsic value of options exercised for the nine September 30, 2023 nine September 30, 2023. The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield. The assumptions used in the Black-Scholes pricing model for options granted during the nine September 30, 2023 2022, Nine Months Ended September 30, 2023 2022 Risk free interest rate 3.5 % - 4.4 % 1.3 % - 3.0 % Expected volatility 48.2 % - 49.4 % 53.8 % - 55.5 % Expected life (years) 4.5 4.5 Expected dividend yield 0.0 % 0.0 % Fair value per option $ 11.46 $ 11.26 As of September 30, 2023, Restricted Stock Units RSUs generally vest in equal annual installments over a three RSU activity for the nine September 30, 2023 Weighted Number of Average Shares Fair Value Outstanding as of December 31, 2022 675,405 $ 28.40 Granted 442,762 $ 26.66 Vested (259,134 ) $ 29.29 Forfeited and cancelled (84,870 ) $ 27.11 Outstanding as of September 30, 2023 774,163 $ 27.25 The weighted-average grant-date fair value per share of RSUs granted was $26.66 and $25.14 for the nine September 30, 2023 2022, nine September 30, 2023 2022, September 30, 2023, Performance Stock Units PSU activity for the nine September 30, 2023 Number of Shares Weighted Average Fair Value Outstanding as of December 31, 2022 117,897 $ 34.98 Forfeited and cancelled (117,897 ) $ 34.98 Outstanding as of September 30, 2023 - $ - The total fair value of PSUs vested was $0 and $0.6 million for the nine September 30, 2023 2022, September 30, 2023, no

Note 12 - Income Taxes

Note 12 - Income Taxes	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. Income Taxes The Company recorded an income tax benefit of $0.5 million and $2.5 million for the three nine September 30, 2023, three nine September 30, 2022, The change in the effective tax rate for the three September 30, 2023, 2022, three September 30, 2023. nine September 30, 2023, 2022, nine September 30, 2023, nine September 30, 2022. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not December 31, 2022, 2023. December 31, 2023 not not three nine September 30, 2023 September 30, 2023, The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in certain foreign jurisdictions. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate, which varies by jurisdiction.

Note 13 - Share Repurchase

Note 13 - Share Repurchase	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Equity [Text Block]	13. Share Repurchase In April 2023, first second On May 12, 2023, May 12, 2023 June 30, 2023. July 2023. July 2023,

Note 14- Earnings Per Share ("E

Note 14- Earnings Per Share ("EPS")	9 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	14. Earnings Per Share ( EPS ) Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not The Company had a net loss during the three nine September 30, 2023 2022, September 30, 2023 2022, September 30, 2023 2022. not

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		ITEM 5. OTHER INFORMATION. Rule 10b5 1 During the fiscal quarter ended September 30, 2023, none 10b5 1 10b5 1
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 3 - Accounts Receivable (T

Note 3 - Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	As of As of September 30, December 31, 2023 2022 Accounts Receivable $ 36,256 $ 36,235 Less: Allowance for credit losses 1,574 1,608 Net balance, end of period $ 34,682 $ 34,627 As of September 30, 2023 2022 Balance, beginning of the period $ 1,608 $ 1,442 Amounts provided 353 448 Amounts recovered (279 ) (60 ) Amounts written off (101 ) (124 ) Translation adjustments (7 ) (140 ) Balance, end of period $ 1,574 $ 1,566

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	September 30, Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Amortized 2023 (Level 1) (Level 2) (Level 3) Cost Cash equivalents: Money Market Funds $ 51,817 $ 51,817 $ - $ - $ 51,817 December 31, Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Amortized 2022 (Level 1) (Level 2) (Level 3) Cost Cash equivalents: Money Market Funds $ 67,801 $ 67,801 $ - $ - $ 67,801

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 2023 2022 Raw materials $ 16,044 $ 20,535 Work-in-process 17,508 10,648 Finished goods 28,556 25,306 Total $ 62,108 $ 56,489 Inventories $ 43,724 $ 39,765 Other long-term assets 18,384 16,724 Total $ 62,108 $ 56,489

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]	December 31, Nine Months Ended September 30, 2023 2022 Less: Accumulated Weighted Currency Less: Average Gross Translation Accumulated Net Book Net Book Useful Value Adjustment Amortization Value Value Life Developed technology $ 89,580 $ (1,608 ) $ (28,032 ) $ 59,940 $ 64,286 15 IPR&D 2,656 (1,006 ) - 1,650 1,650 Indefinite Customer relationships 9,000 - (3,302 ) 5,698 6,373 10 Distributor relationships 4,700 (415 ) (4,285 ) - - 5 Patents 1,000 (189 ) (716 ) 95 131 16 Tradenames 5,200 - (3,821 ) 1,379 2,159 5 Total $ 112,136 $ (3,218 ) $ (40,156 ) $ 68,762 $ 74,599 13

Note 7 - Goodwill (Tables)

Note 7 - Goodwill (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Goodwill [Table Text Block]	Nine Months Ended September 30, 2023 Balance, beginning of period $ 7,339 Effect of foreign currency adjustments (86 ) Balance, ending of period $ 7,253

Note 8 - Accrued Expenses (Tabl

Note 8 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2023 2022 Compensation and related expenses $ 10,966 $ 11,303 Professional fees 3,227 3,145 Operating lease liability - current 2,054 2,073 Discontinuation of software implementation project 1,904 - Income taxes payable 819 810 Clinical trial costs 330 999 Other 513 510 Total $ 19,813 $ 18,840

Note 10 - Revenue and Geograp_2

Note 10 - Revenue and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 OA Pain Management $ 24,888 $ 24,476 $ 76,855 $ 69,533 Joint Preservation and Restoration 13,470 11,821 39,583 36,055 Non-Orthopedic 3,107 3,967 7,253 11,026 $ 41,465 $ 40,264 $ 123,691 $ 116,614
Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]	Three Months Ended September 30, 2023 2022 Percentage of Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 30,831 74 % $ 31,093 77 % Europe 5,420 13 % 4,885 12 % Other 5,214 13 % 4,286 11 % Total $ 41,465 100 % $ 40,264 100 % Nine Months Ended September 30, 2023 2022 Percentage of Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 90,986 74 % $ 87,552 75 % Europe 16,757 13 % 15,973 14 % Other 15,948 13 % 13,089 11 % Total $ 123,691 100 % $ 116,614 100 %

Note 11 - Equity Incentive Pl_2

Note 11 - Equity Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2023
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of revenue $ 181 $ 242 $ 532 $ 645 Research & development 304 397 1,474 1,267 Selling, general & administrative 3,076 3,237 9,422 8,590 Total stock-based compensation expense $ 3,561 $ 3,876 $ 11,428 $ 10,502
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Weighted Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Options Price (in years) (in thousands) Outstanding as of December 31, 2022 1,530,703 $ 34.93 Granted 402,403 $ 28.63 Exercised (2,034 ) $ 18.30 $ 20 Forfeited and canceled (100,628 ) $ 36.40 Outstanding as of September 30, 2023 1,830,444 $ 33.84 7.8 $ 10 Vested, September 30, 2023 975,230 $ 36.70 6.9 $ 0 Vested or expected to vest, September 30, 2023 1,830,444 $ 33.84 7.8 $ 10
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2023 2022 Risk free interest rate 3.5 % - 4.4 % 1.3 % - 3.0 % Expected volatility 48.2 % - 49.4 % 53.8 % - 55.5 % Expected life (years) 4.5 4.5 Expected dividend yield 0.0 % 0.0 % Fair value per option $ 11.46 $ 11.26
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Number of Average Shares Fair Value Outstanding as of December 31, 2022 675,405 $ 28.40 Granted 442,762 $ 26.66 Vested (259,134 ) $ 29.29 Forfeited and cancelled (84,870 ) $ 27.11 Outstanding as of September 30, 2023 774,163 $ 27.25
Schedule of Nonvested Performance-Based Units Activity [Table Text Block]	Number of Shares Weighted Average Fair Value Outstanding as of December 31, 2022 117,897 $ 34.98 Forfeited and cancelled (117,897 ) $ 34.98 Outstanding as of September 30, 2023 - $ -

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	9 Months Ended
	Sep. 30, 2023
Number of Operating Segments	1

Note 3 - Accounts Receivable -

Note 3 - Accounts Receivable - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 01, 2022
Accounts Receivable	$ 36,256		$ 36,235
Less: Allowance for credit losses	1,574		1,608
Net balance, end of period	34,682		$ 34,627
Balance, beginning of the period	1,608	$ 1,442
Amounts provided	353	448
Amounts recovered	(279)	(60)
Amounts written off	(101)	(124)
Translation adjustments	(7)	(140)
Balance, end of period	$ 1,574	$ 1,566

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - Money Market Funds [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Estimate of Fair Value Measurement [Member]
Cash equivalents	$ 51,817	$ 67,801
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	51,817	67,801
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents	0	0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents	0	0
Reported Value Measurement [Member]
Cash equivalents	$ 51,817	$ 67,801

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Inventory Valuation Reserves	$ 11.5	$ 9.9

Note 5 - Inventories - Summary

Note 5 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Raw materials	$ 16,044	$ 20,535
Work-in-process	17,508	10,648
Finished goods	28,556	25,306
Total	62,108	56,489
Inventories	43,724	39,765
Other long-term assets	$ 18,384	$ 16,724

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2023
Amortization of Intangible Assets	$ 1.9	$ 5.8

Note 6 - Acquired Intangible As

Note 6 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Gross value	$ 112,136
Accumulated Currency Translation Adjustment	(3,218)
Current period impairment charge	(40,156)
Accumulated Amortization	68,762
Net book value	68,762		$ 74,599
Useful life (Year)		13 years
Developed Technology Rights [Member]
Gross value	89,580
Accumulated Currency Translation Adjustment	(1,608)
Current period impairment charge	(28,032)
Accumulated Amortization	59,940
Net book value			64,286
Useful life (Year)		15 years
In Process Research and Development [Member]
Gross value	2,656
Accumulated Currency Translation Adjustment	(1,006)
Current period impairment charge	0
Accumulated Amortization	1,650
Net book value			1,650
Customer Relationships [Member]
Gross value	9,000
Accumulated Currency Translation Adjustment	0
Current period impairment charge	(3,302)
Accumulated Amortization	5,698
Net book value			6,373
Useful life (Year)		10 years
Distribution Rights [Member]
Gross value	4,700
Accumulated Currency Translation Adjustment	(415)
Current period impairment charge	(4,285)
Accumulated Amortization	0
Net book value			0
Useful life (Year)		5 years
Patents [Member]
Gross value	1,000
Accumulated Currency Translation Adjustment	(189)
Current period impairment charge	(716)
Accumulated Amortization	95
Net book value			131
Useful life (Year)		16 years
Trade Names [Member]
Gross value	5,200
Accumulated Currency Translation Adjustment	0
Current period impairment charge	(3,821)
Accumulated Amortization	$ 1,379
Net book value			$ 2,159
Useful life (Year)		5 years

Note 7 - Goodwill - Changes in

Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Balance, beginning of period	$ 7,339
Effect of foreign currency adjustments	(86)
Balance, ending of period	$ 7,253

Note 8 - Accrued Expenses - Sum

Note 8 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Compensation and related expenses	$ 10,966	$ 11,303
Professional fees	3,227	3,145
Discontinuation of software implementation project	1,904	0
Income taxes payable	819	810
Clinical trial costs	330	999
Other	513	510
Total	19,813	18,840
Accrued Expenses and Other Current Liabilities [Member]
Operating lease liability - current	$ 2,054	$ 2,073

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Oct. 21, 2021	Sep. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Standard and Extended Product Warranty Accrual, Ending Balance		$ 0		$ 0
Parcus Medical Arbitration [Member]
Loss Contingency, Damages Sought, Value	$ 60,000
Parcus Medical Arbitration [Member] | Pending Litigation [Member]
Payments for Legal Settlements	$ 4,300
Loss Contingency Accrual			$ 3,300

Note 10 - Revenue and Geograp_3

Note 10 - Revenue and Geographic Information (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue from Contract with Customer, Excluding Assessed Tax	$ 41,465	$ 40,264	$ 123,691	$ 116,614
OA Pain Management [member]
Revenue from Contract with Customer, Excluding Assessed Tax	24,888	24,476	76,855	69,533
Veterinary [Member] | OA Pain Management [member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,600	$ 1,200	$ 3,200	$ 4,600
DePuy Synthes Mitek Sports Medicine [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage	44%	45%	45%	43%

Note 10 - Revenue and Geograp_4

Note 10 - Revenue and Geographic Information - Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 41,465	$ 40,264	$ 123,691	$ 116,614
OA Pain Management [member]
Revenue	24,888	24,476	76,855	69,533
Joint Preservation and Restoration [Member]
Revenue	13,470	11,821	39,583	36,055
Non-Orthopedic [Member]
Revenue	$ 3,107	$ 3,967	$ 7,253	$ 11,026

Note 10 - Revenue and Geograp_5

Note 10 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 41,465	$ 40,264	$ 123,691	$ 116,614
Percentage of Revenue	100%	100%	100%	100%
UNITED STATES
Revenue	$ 30,831	$ 31,093	$ 90,986	$ 87,552
Percentage of Revenue	74%	77%	74%	75%
Europe [Member]
Revenue	$ 5,420	$ 4,885	$ 16,757	$ 15,973
Percentage of Revenue	13%	12%	13%	14%
Other Location [Member]
Revenue	$ 5,214	$ 4,286	$ 15,948	$ 13,089
Percentage of Revenue	13%	11%	13%	11%

Note 11 - Equity Incentive Pl_3

Note 11 - Equity Incentive Plan (Details Textual) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Jun. 14, 2023	Sep. 30, 2023	Sep. 30, 2022	Jun. 13, 2023	Nov. 04, 2021	Jun. 13, 2017
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		402,403
Premium-Priced Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Premium Priced Options, Exercise Price as Percentage of Market Price		110%
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 7.2
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 10 months 24 days
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 14.4
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 10 months 24 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 26.66	$ 25.14
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 6.8	$ 5.8
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value			$ 0.6
The 2017 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	435,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	5,285,000			4,850,000
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs (in shares)						2
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		1,000,000				5,285,000
The 2021 Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		5,908
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					125,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years

Note 11 - Equity Incentive Pl_4

Note 11 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stock-based compensation expense	$ 3,561	$ 3,876	$ 11,428	$ 10,502
Cost of Sales [Member]
Stock-based compensation expense	181	242	532	645
Research and Development Expense [Member]
Stock-based compensation expense	304	397	1,474	1,267
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 3,076	$ 3,237	$ 9,422	$ 8,590

Note 11 - Equity Incentive Pl_5

Note 11 - Equity Incentive Plan - Stock Options (Details) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Outstanding, shares (in shares) | shares	1,530,703
Outstanding, Weighted Average Exercise (in dollars per share) | $ / shares	$ 34.93
Granted, shares (in shares) | shares	402,403
Granted, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 28.63
Exercised, shares (in shares) | shares	(2,034)
Exercised, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 18.3
Exercised, Aggregate Intrinsic Value | $	$ 20
Forfeited and canceled, shares (in shares) | shares	(100,628)
Forfeited and canceled, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 36.4
Outstanding, shares (in shares) | shares	1,830,444
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 33.84
Outstanding, Weighted Average Remaining Contractual Term (Year)	7 years 9 months 18 days
Outstanding, Aggregate Intrinsic Value | $	$ 10
Vested, shares (in shares) | shares	975,230
Vested, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 36.7
Vested, Weighted Average Remaining Contractual Term (Year)	6 years 10 months 24 days
Vested, Aggregate Intrinsic Value | $	$ 0
Vested and expected to vest, shares (in shares) | shares	1,830,444
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 33.84
Vested and expected to vest, Weighted Average Remaining Contractual Term (Year)	7 years 9 months 18 days
Vested and expected to vest, Aggregate Intrinsic Value | $	$ 10

Note 11 - Equity Incentive Pl_6

Note 11 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Expected life (years) (Year)	4 years 6 months	4 years 6 months
Expected dividend yield	0%	0%
Fair value per option (in dollars per share)	$ 0.1146	$ 0.1126
Minimum [Member]
Risk free interest rate	3.50%	1.30%
Expected volatility	48.20%	53.80%
Maximum [Member]
Risk free interest rate	4.40%	3%
Expected volatility	49.40%	55.50%

Note 11 - Equity Incentive Pl_7

Note 11 - Equity Incentive Plan - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Outstanding, shares (in shares)	675,405
Outstanding, weighted average grant date fair value (in dollars per share)	$ 28.4
Granted (in shares)	442,762
Granted, weighted average grant date fair value (in dollars per share)	$ 26.66	$ 25.14
Vested, shares (in shares)	(259,134)
Vested, weighted average grant date fair value (in dollars per share)	$ 29.29
Forfeited and cancelled, shares (in shares)	(84,870)
Forfeited and cancelled, weighted average grant date fair value (in dollars per share)	$ 27.11
Outstanding, shares (in shares)	774,163
Outstanding, weighted average grant date fair value (in dollars per share)	$ 27.25

Note 11 - Equity Incentive Pl_8

Note 11 - Equity Incentive Plan - Performance Stock Units (Details) - Performance Shares [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Outstanding, shares (in shares) | shares	117,897
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 34.98
Forfeited and cancelled, shares (in shares) | shares	(117,897)
Forfeited and cancelled, weighted average grant date fair value (in dollars per share) | $ / shares	$ 34.98
Outstanding, shares (in shares) | shares	0
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 0

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Expense (Benefit)	$ (463)	$ (1,187)	$ (2,456)	$ (2,404)
Effective Income Tax Rate Reconciliation, Percent	6.60%	22.10%	11.10%	19.50%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount			$ 700
Domestic Tax Authority [Member] | Change in Effective Tax Rate Due to Discrete Non-deductible Stock Compensation Charge [Member]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount	$ 1,100
Deferred Tax Assets, Valuation Allowance	$ 2,300		$ 2,300

Note 13 - Share Repurchase (Det

Note 13 - Share Repurchase (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended	9 Months Ended
	May 12, 2023	Jul. 31, 2023	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Apr. 30, 2023	Apr. 13, 2023
Payments for Repurchase of Common Stock				$ 5,000	$ 0
Cooperation Agreement [Member]
Stock Repurchase Program, Authorized Amount							$ 20,000
Cooperation Agreement [Member] | Accelerated Stock Repurchase Program with Investment Bank [Member]
Stock Repurchase Program, Authorized Amount						$ 5,000
Cooperation Agreement [Member] | Stock Repurchase Program on Open Market [Member]
Stock Repurchase Program, Authorized Amount						5,000
Cooperation Agreement [Member] | Stock Repurchase Program on Open Market Subject to Positive Cash Flow[Member]
Stock Repurchase Program, Authorized Amount						$ 10,000
Accelerated Stock Repurchase Agreement [Member] | Fixed Dollar Accelerated Share Repurchase Transaction (“ASR Agreement”) [Member] | Bank of America [Member]
Stock Repurchase Program, Authorized Amount	$ 5,000
Payments for Repurchase of Common Stock	$ 5,000
Stock Repurchased During Period, Shares (in shares)	158,983	29,046
Accelerated Share Repurchases, Initial Price Paid Per Share (in dollars per share)	$ 25.16
Accelerated Share Repurchases, Percentage of Shares Repurchased	80%
Accelerated Share Repurchases, Final Price Paid Per Share (in dollars per share)		$ 26.59
Accelerated Stock Repurchase Agreement [Member] | Fixed Dollar Accelerated Share Repurchase Transaction (“ASR Agreement”) [Member] | Bank of America [Member] | Additional Paid-in Capital [Member]
Treasury Stock, Value, Acquired, Par Value Method			$ 5,000

Note 14- Earnings Per Share (_2

Note 14- Earnings Per Share ("EPS") (Details Textual) - shares shares in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1.8	1.5
Restricted Stock Units and Performance Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0.8	0.8